

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

FERRING PHARMACEUTICALS INC.,
FERRING INTERNATIONAL CENTER
S.A., FERRING B.V., and
POLYPEPTIDE LABORATORIES A/S

Plaintiffs,

V.

FRESENIUS KABI USA, LLC,

Defendant.

C.A. No. 20-cv-431 (MN)

NOTICE OF APPEAL

NOTICE IS HEREBY GIVEN that Plaintiffs Ferring Pharmaceuticals Inc., Ferring International Center S.A., Ferring B.V., and Polypeptide Laboratories A/S (collectively, “Plaintiffs”) hereby appeal to the United States Court of Appeals for the Federal Circuit from the District Court’s Final Judgment entered on January 30, 2023 (D.I. 234), and all rulings, proceedings, orders, findings, opinions and decisions (whether oral or written) underlying the Final Judgment, including, but not limited to, the Court’s Memorandum Opinion (D.I. 223) dated December 22, 2022, and the related Order entered on December 22, 2022 (D.I. 224).

Dated: January 30, 2023

Respectfully submitted,

/s/ Mary W. Bourke

Mary W. Bourke (#2356)

Dana K. Severance (#4869)

Daniel M. Attaway (#5130)

John B. Bourke (#6534)

WOMBLE BOND DICKINSON (US) LLP

1313 North Market Street, Suite 1200

Wilmington, DE 19801

Telephone: (302) 252-4320

Mary.Bourke@wbd-us.com

Dana.Severance@wbd-us.com

Daniel.Attaway@wbd-us.com

Ben.Bourke@wbd-us.com

OF COUNSEL:

Joshua P. Davis

WOMBLE BOND DICKINSON (US) LLP

811 Main Street, Suite 3130

Houston, TX 77002

Counsel for Plaintiffs